• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    11/6/23 3:57:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THRN alert in real time by email
    SC 13G/A 1 tm2330008d1_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Thorne Healthtech, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    885260 109

    (CUSIP Number)

     

    October 16, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b) 

    ¨ Rule 13d-1(c) 

    x Rule 13d-1(d) 

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of the section of the Act but shall be subject to all other provisions of that Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 885260 109

     

     1   

     NAMES OF REPORTING PERSONS

     

     Kirin Holdings Company, Limited

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ¨  (b) x

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Japan

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      5   

     SOLE VOTING POWER

     

     0

      6  

     SHARED VOTING POWER

     

     0

      7  

     SOLE DISPOSITIVE POWER

     

     0

      8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ¨

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     0

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO

     

     

     

     

    This Amendment No. 2 to the Schedule 13G (“Amendment No. 2”) relating to Thorne Healthtech, Inc., a Delaware corporation (the “Issuer”), is being filed on behalf of the undersigned to amend the Schedule 13G filed with the Securities and Exchange Commission on February 14, 2023, as amended (the “Schedule 13G”). This Amendment No. 2 is the final amendment to the Schedule 13G and is an exit filing.

     

    Item 1.

     

      (a) Name of Issuer:

     

    Thorne Healthtech, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    152 W 57th Street, New York, NY 10019

     

    Item 2.  

     

      (a) Name of Person Filing:

     

    Kirin Holdings Company, Limited

     

      (b) Address of Principal Business Office or, if none, Residence

     

    Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo 164-0001, Japan

     

      (c) Citizenship:

     

    Japan

     

      (d) Title of Class of Securities:

     

    common stock, par value $0.01 per share

     

      (e) CUSIP Number:

     

    885260 109

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    Item 4. Ownership

     

    The information required by Items 4(a)—(c) is set forth in Rows 5-9 and 11 of the cover page for the Reporting Person and is incorporated herein by reference.

     

    On August 27, 2023, the Issuer entered into an Agreement and Plan of Merger with Healthspan Buyer, LLC and Healthspan Merger Sub, Inc. (“Purchaser”) pursuant to which Purchaser commenced a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of the Issuer, $0.01 par value per share (the “Company Capital Stock”). Following the expiration time of the Offer, Purchaser accepted the Company Capital Stock validly tendered pursuant to the Offer at a purchase price of $10.20 per share in cash, without interest and subject to applicable withholding taxes. As a result, as of October 16, 2023, the Reporting Person is no longer the beneficial owner of any securities of the Issuer.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certification.

     

    Not applicable.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 2, 2023

     

    KIRIN HOLDINGS COMPANY, LIMITED  
         
    By: /s/ Takeshi Minakata    
      Name: Takeshi Minakata  
      Title: Director, Senior Executive Officer  

     

     

     

    Get the next $THRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THRN

    DatePrice TargetRatingAnalyst
    11/17/2022$5.50Buy
    Canaccord Genuity
    10/18/2021$11.00Buy
    B of A Securities
    10/18/2021Buy
    BofA Securities
    10/18/2021$13.00Outperform
    Evercore ISI Group
    10/18/2021$11.00Outperform
    Cowen & Co.
    10/18/2021$11.00Outperform
    RBC Capital
    More analyst ratings

    $THRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Varma Saloni S. returned 581,643 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 5:01:44 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mckenna Thomas P. returned 1,172,227 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 5:00:39 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mccamy William C. returned 589,804 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 4:59:36 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    SEC Filings

    View All

    SEC Form 15-12G filed by Thorne Healthtech Inc.

    15-12G - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/26/23 6:03:57 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Thorne Healthtech Inc.

    S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/16/23 4:54:57 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Thorne Healthtech Inc.

    S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/16/23 4:53:59 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    L Catterton and Thorne HealthTech, Inc. Announce Expiration of Tender Offer

    NEW YORK, Oct. 13, 2023 /PRNewswire/ -- L Catterton and Thorne HealthTech, Inc. ("Thorne") (NASDAQ:THRN) today announced that the tender offer to purchase all of the issued and outstanding shares of Thorne's common stock ("Shares") for $10.20 per Share, net to the seller in cash, without interest and less any required withholding taxes (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on October 12, 2023 and was not extended (such date and time, the "Expiration Time"). Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised L Catterton that, as of the Expiration Time, 52,596,517 Shares were validly tendered and not validly

    10/13/23 8:00:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifshitz Law PLLC Announces Investigations of ABCM, THRN, BHRB, and AGE

    NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Abcam Plc (NASDAQ:ABCM) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ABCM to Danaher Corporation for $24.00 per share in cash for each share of ABCM common stock owned. If you are an ABCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Thorne HealthTech, Inc. (NASDAQ:THRN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TRHN to L Catter

    9/2/23 7:47:00 PM ET
    $ABCM
    $BHRB
    $THRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Banks
    Finance

    Thorne HealthTech, Inc. Enters into Definitive Agreement to be Acquired by L Catterton for $10.20 Per Share in Cash

    L Catterton to Commence a Tender Offer for all of Thorne's Outstanding Shares of Common Stock Thorne Stockholders to Receive $10.20 per Share in Cash, Representing a 94% Premium to the Unaffected Price Independent Special Committee and Thorne Board of Directors Unanimously Approve Transaction and Recommend that All Stockholders Tender Their Shares in the Tender Offer  NEW YORK, Aug. 28, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused inv

    8/28/23 8:00:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Thorne HealthTech with a new price target

    Canaccord Genuity initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $5.50

    11/17/22 7:24:31 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B of A Securities initiated coverage on Thorne HealthTech with a new price target

    B of A Securities initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $11.00

    10/18/21 10:22:55 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Thorne HealthTech

    BofA Securities initiated coverage of Thorne HealthTech with a rating of Buy

    10/18/21 9:20:07 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Financials

    Live finance-specific insights

    View All

    Thorne HealthTech Reports Second Quarter 2023 Results

    Record Net Sales With Growth of 33.1%; Raises Full-Year Guidance Midpoints for Net Sales and Gross Margin NEW YORK, Aug. 8, 2023  /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the second quarter ended June 30, 2023. Second Quarter Highlights: Net sales grew 33.1% year-over-year to $72.7 million, with direct-to-consumer ("DTC") sales growth of 39.3%Gross profit grew 35.7% year-over-year to $40.6 million; gross profit as a % of net sales increased year-over-year to 55.9%.Net incom

    8/8/23 4:05:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thorne HealthTech Schedules Second Quarter 2023 Earnings Release and Conference Call for August 8

    Company Withdraws Participation in the Canaccord Genuity 43rd Annual Growth Conference on Aug. 10 NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, will release its second quarter 2023 financial results after market close on Tuesday, Aug. 8, 2023. The company will host a conference call to discuss its results on Tuesday, Aug. 8, 2023, at 5:00 p.m. (U.S. Eastern Time). A live webcast and replay of the call will be available on the investors section of the

    8/1/23 5:15:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thorne HealthTech Reports First Quarter 2023 Results

    Net Sales Growth of 20.7%; Reaffirms Full-Year 2023 Guidance NEW YORK, May 11, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Highlights: Net sales grew 20.7% year-over-year to $65.2 million, with direct-to-consumer ("DTC") sales growth of 41.0%Gross profit grew 16.3% year-over-year to $34.3 million; gross p

    5/11/23 4:05:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Leadership Updates

    Live Leadership Updates

    View All

    Thorne HealthTech Appoints Saloni Varma as New Chief Financial Officer

    NEW YORK, March 13, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ:THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced that it has appointed Saloni Varma as Chief Financial Officer (CFO). As CFO, Varma will lead all aspects of the company's Accounting and Finance functions including budgeting planning and analysis, accounting, SEC reporting, tax, treasury, and investor relations. Varma brings more than 20 years of experience across a range of consumer goods companies, mos

    3/13/23 7:30:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    11/6/23 3:57:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    10/17/23 4:10:56 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    2/10/23 5:04:59 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care